The present disclosure relates generally to stimulation devices, systems, and methods of use thereof. The stimulation systems may be used to stimulate the cornea and/or conjunctiva and/or subconjunctiva of the eye to increase tear production in the treatment of one or more indications, such as dry eye.
Dry eye is a condition that affects millions of people. More than 40 million people in North America have some form of dry eye, and many millions more suffer worldwide. Dry eye results from the disruption of the natural tear film on the surface of the eye, and can result in ocular discomfort, visual disturbance and a reduction in vision-related quality of life. Activities of daily living such as driving, computer use, housework, and reading have also been shown to be negatively impacted by dry eye. Patients with severe cases of dry eye are at risk for serious ocular health deficiencies such as corneal ulceration, and can experience a quality of life deficiency comparable to that of moderate-severe angina.
Dry Eye Disease (“DED”) is a clinical condition of the eye. DED is progressive in nature, and fundamentally results from insufficient tear coverage on the surface of the eye. This poor tear coverage prevents healthy gas exchange and nutrient transport for the ocular surface, promotes cellular desiccation, and creates a poor refractive surface for vision. Poor tear coverage typically results from: 1) insufficient aqueous tear production from the lacrimal glands (e.g. secondary to post-menopausal hormonal deficiency, autoimmune disease, LASIK surgery, etc.), and/or 2) excessive evaporation of aqueous tear resulting from dysfunction of the meibomian glands. Low tear volume causes a hyperosmolar environment that induces an inflamed state of the ocular surface. This inflammatory response induces apoptosis of the surface cells, which in turn prevents proper distribution of the tear film on the ocular surface so that any given tear volume is rendered less effective. This initiates a vicious cycle where more inflammation can ensue, causing more surface cell damage, etc.
External factors that are not clinically based may also contribute to dry eye. These factors can include medications, dehydration, and environmental pollutants. Contact lenses, particularly soft contact lenses, are also known to cause or exacerbate the symptoms of dry eye. The contact lenses continually absorb water from the surface of the tear film in order to keep hydrated, leading to dryness of the eye. Dry eye can also be a symptom of the condition commonly known as “tired eye.” During extended periods of focused, intense use, such as heavy computer use and long distance driving, the eyes strain and blink less frequently, which can lead to insufficient lubrication of the eyes (i.e., dry eye).
There is a wide spectrum of treatments for dry eye, although without substantial efficacy for treatment of the condition. Treatment options include: artificial tear substitutes, ointments, gels, warm compresses, environmental modification, topical cyclosporine, omega-3 fatty acid supplements, punctal plugs, and moisture chamber goggles. Patients with severe disease may further be treated with punctal cautery, systemic cholinergic agonists, systemic anti-inflammatory agents, mucolytic agents, autologous serum tears, PROSE scleral contact lenses, and tarsorrhaphy. Despite these treatment options, dry eye continues to be considered one of the most poorly treated diseases in ophthalmology. Accordingly, it would be desirable to have a more effective treatment for dry eye.
Described here are devices, systems, and methods for increasing tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva. Generally, the devices and systems may be configured to electrically stimulate the cornea and/or conjunctiva and/or subconjunctiva. In some variations, the devices may comprise a stimulator chip. An external power source may wirelessly transmit energy to the stimulator chip, where the stimulator chip may convert the energy transmitted to an electric waveform and electrically stimulate the cornea, conjunctiva and/or subconjunctiva. Stimulation may activate reflex pathways to increase tear production. The devices and systems for increasing tear production may be used in methods of treating dry eye, reducing the symptoms of tired eye, increasing comfort for contact lens wearers, and extending the number of years a contact lens user can wear contacts. Also described are methods of manufacturing a contact lens, where the contact lens is configured to increase tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva.
In some variations, the devices described here may comprise lens devices for increasing tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva of a subject. The devices may be in the form of a contact lens for placement on the cornea/conjunctiva of the eye. The contact lens may comprise a lens body and a stimulator chip, where the stimulator chip is within the lens body. Energy transmitted from the external power source to the stimulator chip may be converted to electrically stimulate the cornea, conjunctiva, and/or subconjunctiva. The lacrimal pathway may be initiated with activating sensory components in the cornea, conjunctiva, subconjunctiva, or surrounding orbital tissue. Stimulation may activate the lacrimal reflex to increase tear production.
In some variations, the devices described here may comprise implantable devices for increasing tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva of a subject. In some variations, the device may be in the form of an implantable device comprising a stimulator chip. The implantable device may utilize reflex pathways to activate the lacrimal gland, and in some cases the accessory glands, such as krause, zeiss, and meibomian glands, to increase tear production and tear quality. The implantable device may be placed subconjunctivally.
In some variations, the systems described here comprise systems for increasing tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva of a subject. In some variations, the system may comprise a device having a stimulator chip and an external power source. The external power source may be handheld or mountable for mounting to locations adjacent to where a patient may look for extended periods of time (e.g., a computer monitor, car windshield, television, etc.). The stimulator chip may receive wireless energy from the external power source and provide an electric stimulation waveform to the corneal and/or conjunctival innervation of the eye to increase tear production. In some variations, the external power source may be a laser diode or a light-emitting diode (LED), which may in some instances emit infrared (IR) light.
In some variations, the methods described here may comprise methods for increasing tear production in a subject. In some variations, the methods for increasing tear production may be used for treating DED caused by clinical factors, such as dysfunction of the lacrimal and/or meibomian glands. The treatment may also be for dry eye caused by external factors, such as medications, dehydration, and environmental pollutants. In some variations, the methods for increasing tear production may be for increasing comfort for contact lens wearers. In some variations, the methods for increasing tear production may be for reducing the symptoms of tired eye in patients not diagnosed as having DED. In some variations, the methods for increasing tear production may be for extending the number of years a contact lens user can wear contacts. The methods may comprise the step of stimulating the cornea, conjunctiva, and/or subconjunctiva to activate the reflex pathway and increase lacrimation.
In some variations, the methods described here comprise methods of manufacturing a contact lens configured to increase tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva. The method of manufacturing a contact lens may comprise the step of embedding a stimulator chip in a lens body by sheet casting or rod casting. The method may further comprise the step of lathe cutting the casting to a desired shape. In some variations, the method of manufacturing a contact lens may comprise embedding a stimulator chip in a lens body and shaping the lens body by direct cast molding.
In some variations, the devices described here comprise a contact lens for increasing tear production in an eye of a subject. In some variations, the contact lens comprises a lens body configured for placement on a surface of the eye, and a stimulator chip configured to stimulate a cornea or a conjunctiva of the eye, where the stimulator chip is embedded within the lens body. In some variations, the lens body is a corrective lens. In some of these variations, the corrective lens is toric, aspheric, multifocal, diffractive, or scleral. In some variations, the lens body is non-corrective or non-refractive and has a zero power. In some variations, the lens body has a posterior surface configured to contact the conjunctiva of the eye, and the stimulator chip is embedded in the lens body within 20 microns of the posterior surface. In some variations, the stimulator chip is embedded in a portion of the lens body that is configured to cover an iris of the eye when the lens body is placed on the surface of the eye. In some variations, the stimulator chip is embedded in a portion of the lens body that is configured to be in front of an iris of the eye when the lens body is placed on the cornea of the eye. In some variations, the contact lens comprises a counterweight located approximately 180 degrees from the stimulator chip. In some of these variations, the counterweight is a second stimulator chip. In some variations, the contact lens comprises one or more weights for minimizing rotation of the contact lens. In some of these variations, the one or more weights is a second stimulator chip. In some variations, the stimulator chip is configured to receive energy wirelessly from an external power source and to convert the energy to a stimulation signal for electrically stimulating the cornea or the conjunctiva. In some of these variations, the stimulator chip comprises a power receiver configured to receive the energy wirelessly and to convert the energy to an electric signal. In some of these variations, the stimulator chip further comprises a signal conditioning unit configured to receive the electric signal and to modify the electric signal into an electric output. In some of these variations, modifying the electric signal comprises modifying one or more of a frequency, a shape, and an amplitude of the electric signal. In some variations, the stimulator chip further comprises electrode contacts configured to deliver the electric output to the cornea or the conjunctiva. In some of these variations, the electric output has a frequency that varies over time. In others of these variations, the electric output has a pulse width that varies over time. In some variations, the stimulator chip comprises a photodiode. In some variations, the stimulator chip comprises an integrated circuit. In some variations, the stimulator chip has a thickness between approximately 5 microns and 100 microns. In some of these variations, the thickness of the stimulator chip is approximately 20 microns.
In some variations, the systems described here are for increasing tear production in an eye of a subject. In some variations, the systems comprise a device configured for placement on a cornea, or in a subconjunctiva of the eye, where the device comprises a stimulator chip configured to stimulate the cornea or a conjunctiva of the eye, and an external power source for transmitting energy wirelessly to the stimulator chip to activate the stimulator chip. In some variations, the external power source is handheld. In other variations, the external power source is mountable. In some variations, the external power source comprises a laser diode. In some of these variations, the laser diode produces light comprising wavelengths between approximately 880 nm and 930 nm. In some variations, the external power source comprises an infrared light-emitting diode. In other variations, the external power source comprises an optical modifier to produce non-collimated light. In some of these variations, the optical modifier comprises a condenser lens and a microlens array. In some variations, the stimulator chip comprises a photodiode.
Also described here are methods of increasing tear production in a subject. In some variations, the methods comprise transmitting energy wirelessly from an external power source to a stimulator chip, where the stimulator chip is located in a subconjunctival space of an eye of the subject or is embedded in a contact lens worn by the subject, and delivering a stimulus from the stimulator chip to a conjunctiva or a cornea of the eye to produce tears. In some variations, the stimulator chip comprises a photodiode, and the external power source comprises a light source. In some of these variations, the light source comprises a laser diode. In other of these variations, the light source comprises an infrared light-emitting diode. In some variations, the method further comprises moving the eye to expose the photodiode to the light source. In some variations, the external power source is fixed to a location selected from the group consisting of a computer monitor, a car windshield, a television, and a forward face of a smart phone or a tablet. In some variations, the stimulator chip is within an implantable device located in the subconjunctival space of the eye. In some of these variations, the implantable device is secured in the subconjunctival space of the eye by one or more anchors. In some variations, the method further comprises periodically replacing the implantable device. In some of these variations, replacing the implantable device comprises removing the existing implantable device from a first location and placing a new implantable device in a second location. In some variations, the subject has dry eye, and the method of increasing tear production is used to treat the dry eye. In some variations, the subject is at an increased risk of developing dry eye, and the method of increasing tear production is used for prophylactic treatment of dry eye. In some variations, the subject has ocular allergies, and method of increasing tear production is used to treat the ocular allergies. In some variations, the subject wears contact lenses, and the method of increasing tear production is used for increasing comfort of wearing contact lenses. In some variations, the subject wears contact lenses, and the method of increasing tear production is used for extending a time period for which the subject can comfortably wear contact lenses. In some variations, the subject wears contact lenses, and the method of increasing tear production is used for extending a number of years for which the subject can wear contact lenses. In some variations, the subject has tired eye, and the method of increasing tear production is used for reducing symptoms of tired eye.
Also described here are methods for manufacturing a contact lens configured to treat dry eye. In some variations, the method comprises embedding a stimulator chip in a lens body, and shaping the lens body. In some variations, embedding comprises sheet casting. In other variations, embedding comprises rod casting. In some variations, shaping comprises lathe cutting. In some variations, the method comprises cast molding. In some variations, the contact lens has a posterior surface configured to contact a conjunctiva of an eye, and the stimulator chip is embedded in the lens body proximate to the posterior surface at a distance sufficient to allow for effective stimulation of a cornea and/or the conjunctiva of the eye by the stimulator chip.
Described here are devices, systems, and methods for increasing tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva. The device may be a contact lens or an implantable device, which may comprise a stimulator chip. The system may comprise the contact lens or implantable device and an external power source that may wirelessly transmit energy to the stimulator chip. The stimulator chip may convert the energy transmitted to an electric waveform, which may be delivered to a subject to electrically stimulate the cornea, conjunctiva, and/or subconjunctiva. This may in turn activate the reflex pathways and increase tear production.
The devices and systems for increasing tear production described here may be used in methods of treating dry eye caused by clinical and/or external factors. They may also be used in methods of reducing the symptoms of tired eye, increasing comfort for contact lens wearers, and extending the number of years a contact lens user can wear contacts. Also described are methods of manufacturing a contact lens, where the contact lens is configured to increase tear production by stimulating the cornea and/or conjunctiva.
Devices
The devices described here may be for placement on the cornea or for placement in the subconjunctiva of the eye. The devices may comprise a stimulator chip for electrically stimulating the cornea and/or conjunctiva to increase lacrimation in patients suffering from dry eye, tired eye, and other conditions.
Contact Lens
As shown in
The contact lens may be corrective having a power specific to the patient's needs. The contact lens may also be a toric, aspheric, multifocal, diffractive, scleral, or other type of corrective contact lens. Alternatively, the lens may be non-corrective/refractive (i.e., zero power) for patients who do not require corrective lenses but suffer from dry eye, tired eye, or other eye conditions. The lens also may be a bandage contact lens for protecting and healing the eye and increasing comfort for patients with damaged or compromised corneas.
Contact lens 110 comprises a stimulator chip 114 within the lens body 112. Stimulator chip 114 may be configured to convert wireless energy transmitted from an outside source to an electric waveform for electrically stimulating the cornea/conjunctiva. Stimulator chip 114 is embedded in the lens body 112 and is positioned close to the posterior surface 116 adjacent to the eye. Close proximity of the stimulator chip to the eye surface may allow for effective stimulation of the cornea and/or conjunctiva. Accordingly, in some variations, the stimulator chip may be within 5 microns, within 10 microns, or within 10-20 microns of the posterior surface of the lens. Larger stimulators may be positioned further from the posterior surface. In other variations, the stimulator chip may be within 50-100 microns of the posterior surface. In other variations, such as with hybrid lens bodies described herein, the stimulator chip may be mounted directly to the surface of the lens body. The stimulator chip may be located in a number of positions in the lens body, but it may be desirable for the stimulator chip to be located in the portion of the lens body that covers the iris of the eye when inserted, so as to avoid blocking the visual axis.
In some instances it may be desirable that the contact lens be rotationally unstable to allow repositioning of the stimulator chip when blinking. This may reduce accommodation and habituation to the stimulus. In one variation, a single stimulator chip embedded in the lens body is light enough in weight to not unbalance the contact lens or prevent repositioning. In another variation, shown in
However, in other instances such rotational instability may be undesirable. For example, contact lenses used for astigmatism are generally toric lenses having different optical power and focal length in two perpendicular orientations. In these cases, rotation of the lens may negatively affect vision, and therefore may not be desirable. In some variations for addressing astigmatism, one, two, or more inactive chips, or other weights, may be placed in the lower portion of the lens body in order to help the lens find a specific orientation and minimize rotation.
Implantable Device
In another variation, the device may be in the form of an implantable device. The implantable device may comprise a stimulator chip that is implanted within the eye and may utilize reflex pathways to provide activation to the lacrimal gland to increase tear production, and in some cases to provide activation of the accessory glands.
The implantable device may in some instances be placed subconjunctivally. The implantable device may be implanted in any location in the subconjunctiva where the stimulator chip can be exposed to energy transmission from an external power source. As shown in
Because the conjunctiva defines an open space between it and the cornea, an implantable device inserted in the subconjunctival space may tend to migrate. Accordingly, the implantable device may comprise one or more fixation features to secure it in place. In some variations, fixation features may include one or multiple feet extending from the device. The feet may measure approximately 50-100 microns in length. In some instances, the feet may be pushed into the sclera for anchorage. Fixation features may also include an angled pick or nail for holding the device in place, biocompatible glue for initial fixation, or any other suitable anchoring feature.
The stimulator chip may have a coating of a thickness that allows the stimulation device to be atraumatic and non-irritating when implanted in the eye, but close enough to the conjunctiva to stimulate the nerves therein. Close proximity of the stimulator chip to the eye surface may allow for effective stimulation of the cornea, conjunctiva, and/or subconjunctiva, while exposure may result in a foreign body sensation and irritation. Accordingly, in some variations, the stimulator chip may have a coating that is between about 5 microns and about 20 microns thick. In some variations, a coating may comprise a hydrogel in order to allow for ionic conduction.
Stimulator Chip
More specifically, the stimulator chip 406 may comprise a power receiver 403 and a signal conditioning unit 405. The power receiver 403 may be supplied with wireless energy from the external power source 401, and may convert the wireless energy to an electric signal Ein. The signal conditioning unit 405 may receive the electric signal Ein and then modify the electric signal Ein into the desired electric output Eout. The signal conditioning unit 405 may modify one or more of the signal's frequency, shape, and amplitude in any suitable manner (e.g., using resistive and capacitive elements, amplifiers). The electric output Eout may be a desired stimulation signal and may be delivered via electrode contacts to the cornea/conjunctiva 408 to activate lacrimation. While the variation of the system described with respect to
In some variations, the stimulator chip may comprise one or more photodiodes, which act as both the power receiver and the signal conditioning unit.
The electrodes may each have dimensions (e.g., a diameter) measuring between 50 microns and 150 microns, specifically between 75 microns and 125 microns, or more specifically approximately 100 microns. This may result in an area of neural activation of approximately 100 microns. The electrodes may be made from any suitable material, such as but not limited to platinum or iridium oxide films. The stimulator chip may have a length measuring between 0.5 mm and 1.5 mm, specifically between 0.75 mm and 1.25 mm, or more specifically approximately 1.0 mm. The stimulator chip may have a width measuring between 0.5 mm and 1.5 mm, specifically between 0.75 mm and 1.25 mm, or more specifically approximately 1.0 mm. The stimulator chip may have a thickness measuring between 5 microns and 100 microns, specifically between 10 microns and 50 microns, or more specifically approximately 20 microns. In some variations, the stimulator chip measures 1.0 mm×1.0 mm×20 microns. The above-mentioned dimensions are exemplary only, and are not limited to the ranges provided. The stimulation chip and components thereof may be actually be larger, as their size may be limited only by the ability for the stimulator chip to fit within the contact lens and not block vision, while meeting the cosmetic requirements of the patient.
External Power Source
The external power source may be configured to wirelessly transmit energy to the stimulator chip. The external power source may comprise an on/off switch so it can be turned off when not in use by the patient. The external power source may be handheld or mountable for mounting to locations adjacent to where a patient may look for extended periods of time. Mounting locations include, but are not limited to, a computer monitor, car windshield, television, forward face of a smart phone, tablet, etc. In some variations, the mounting location may be on the frame of eyeglasses. A subject wearing a contact lens or having an implant as described herein may activate the stimulator chip by exposing a portion of the stimulator chip (e.g., a photodiode) to the power source. Moving the eye (e.g., looking up) may expose the stimulator chip to the energy transmitted by the power source.
In some variations in which the stimulator chip comprises a photodiode, the power source may comprise a light source, such as a laser diode. A laser diode may produce light within a relatively narrow wavelength band. This wavelength band may be chosen to be specific to the wavelength needed to excite the photodiode, while also avoiding wavelengths visible to humans. The responsivity curve of silicon-based photodiodes may end at approximately 1100 nm, while the human eye may be unable to see high intensity infrared light at wavelengths above approximately 850 nm. Therefore, it may be desirable to select a laser diode producing light comprising wavelengths in the range of approximately 880 nm to approximately 930 nm.
The desired wavelength range and power of the light transmitted by the power source may provide the energy required to cause the photodiode to generate current, without being phototoxic to the cornea and/or retina. To avoid harming the retina, it may be desirable for the intensity of the source to be below the levels known to cause damage to the retina, as specified in the American National Standard Institute (ANSI) Standards. In some variations, it may be desirable for the intensity of the source to be below the intensity of sunlight. If a photodiode in a stimulator chip as described herein has a surface area of 1 mm2, for example, pulsing the source at a 1% duty cycle may allow for a safe power range up to 100 mW. In some variations, the external power source described herein may emit 10 mW, pulsed at a 1% duty cycle, which is well within a safe range. The power that may be needed to be delivered to the photodiode may vary by device construction. In some variations, for example, the photodiode may require a power of approximately 0.1 mA to approximately 2 mA to generate a desired stimulation signal, and a light intensity of approximately 1 mW/mm2 to approximately 5 mW/mm2 may be needed to generate this. In some variations, the photodiode may require a power of approximately 1 mA to generate a desired stimulation signal, and a light intensity of approximately 3 mW/mm2 may be needed to generate this. However, it should be appreciated that the powers and light intensities desired may vary largely depending on implementation, and the power and intensity desired may increase for chips comprising more than one photodiode (e.g., may in some variations approximately double or triple for variations that utilize two or three diodes, respectively).
It may be desirable for the output of the external light source to be non-collimated. As shown in the diagram of
By manipulating the external power source, the electric signals delivered to the subject may be tailored for specific treatment regimens and/or specific subjects. The waveforms may be pulse-based or continuous. When the stimulator is configured to deliver a continuous waveform, the waveform may be a sinusoidal in amplitude and/or pulse-width, or quasi-sinusoidal, square-wave, sawtooth/ramped, or triangular waveform, truncated-versions thereof (e.g., where the waveform plateaus when a certain amplitude is reached), or the like.
In some variations, the stimulator may be configured to vary the frequency and/or pulse width of the waveform. This variation may occur according to a pre-determined plan, or may be configured to occur randomly within given parameters. For example, in some variations the continuous waveform may be configured such that the frequency or pulse width of the waveform varies over time (e.g., according to a sinusoidal function having a beat frequency). In some instances varying the frequency and/or pulse width of a stimulation waveform over time, or pulsing the stimulus on and off (e.g., 1 second on/1 second off, 5 seconds on/5 seconds off), may help reduce subject habituation (in which the subject response to the stimulation decreases during stimulation). Additionally or alternatively, ramping the amplitude of the stimulation waveform at the beginning of stimulation may increase comfort. Patterning may achieve a stronger reflex activation and thereby elicit more tearing in both eyes from stimulation in only one eye.
When the stimulator is configured to create a pulse-based electrical waveform, the pulses may be any suitable pulses (e.g., a square pulse, a haversine pulse, or the like). The pulses delivered by these waveforms may by biphasic, alternating monophasic, or monophasic, or the like. When a pulse is biphasic, the pulse may include a pair of single phase portions having opposite polarities (e.g., a first phase and a charge-balancing phase having an opposite polarity of the first phase). In some variations, it may be desirable to configure the biphasic pulse to be charge-balanced, so that the net charge delivered by the biphasic pulse is approximately zero. In some variations, a biphasic pulse may be symmetric, such that the first phase and the charge-balancing phase have the same pulse width and amplitude. In other variations, a biphasic pulse may be asymmetric, where the amplitude and/or pulse width of the first pulse may differ from that of the charge-balancing phase. Additionally, each phase of the biphasic pulse may be either voltage-controlled or current-controlled. In some variations, both the first phase and the charge-balancing phase of the biphasic pulse may be current-controlled. In other variations, both the first phase and the charge-balancing phase of the biphasic pulse may be voltage-controlled. In still other variations, the first phase of the biphasic pulse may be current-controlled, and the second phase of the biphasic pulse may be voltage-controlled, or vice-versa.
In variations where the waveform comprises a biphasic pulse, the biphasic pulse may have any suitable frequency, pulse widths, and amplitudes. For example, in instances where the stimulators described here are used to treat dry eye or otherwise produce a tearing response by stimulating the cornea and/or conjunctiva, the stimulator may be configured to generate a biphasic pulse waveform at a frequency between about 0.1 Hz and about 200 Hz. In some of these variations, the frequency is preferably between about 10 Hz and about 60 Hz. In some of these variations, the frequency is preferably between about 25 Hz and about 35 Hz. In others of these variations, the frequency is preferably between about 50 Hz and about 90 Hz. In some of these variations, the frequency is preferably between about 65 Hz and about 75 Hz. In other variations, the frequency is preferably between about 130 Hz and about 170 Hz. In some of these variations, the frequency is preferably between about 145 Hz and about 155 Hz. In some variations, high frequencies, such as those between about 145 Hz and about 155 Hz may be too high for each pulse to stimulate/activate the target nerves. As a result, the stimulation may be interpreted by the patient to have an element of randomness, which in turn may help to reduce subject habituation.
Similarly, when the stimulus is electrical and the first phase of the biphasic pulse is current-controlled, the first phase may preferably have an amplitude between about 10 μA and 20 mA. In some of these variations, the amplitude may be preferably between about 0.1 mA and about 10 mA. When the first phase of the biphasic pulse is voltage-controlled, the first phase may preferably have an amplitude between about 10 mV and about 25 V. Additionally, the first phase may preferably have a pulse width between about 1 μs and about 10 ms. In some of these variations, the pulse width may preferably be between about 10 μs and about 100 μs. In other variations, the pulse width may preferably be between about 100 μs and about 1 ms.
When an electrical pulse waveform is an alternating monophasic pulsed waveform, each pulse delivered by the stimulator may have a single phase, and successive pulses may have alternating polarities. Generally, the alternating monophasic pulses are delivered in pairs at a given frequency (such as one or more of the frequencies listed above, such as between 30 Hz and 50 Hz), and may have an inter-pulse interval between the first and second pulse of the pair (e.g., about 100 μs, between 50 μs and 150 μs or the like). Each pulse may be current-controlled or voltage-controlled, and consecutive pulses need not be both current-controlled or both voltage-controlled. In some variations where the pulse waveform is charged-balanced, the waveform may comprise a passive charge-balancing phase after delivery of a pair of monophasic pulses, which may allow the waveform to compensate for charge differences between the pulses.
As an alternative to optical coupling, power may be transferred to the stimulator chip from the external source using electromagnetic coupling or an electromagnetic telemetry link. For example, in some variations, the contact lens or implant may comprise an inductive coil and rectification circuit. In such variations, the external power source may be manipulated to control the frequency and pulse-width modulation of the stimulation signal.
Systems
A system as described herein may comprise a device having a stimulator chip and an external power source. The two components may be structurally and functionally configured to work together to increase tear production by stimulating the cornea, conjunctiva, and/or subconjunctiva. The external power source may deliver power and/or signal appropriate to activate the stimulator chip.
Methods
The methods described here may comprise methods for treating dry eye and increasing tear production. Also described are methods for manufacturing a contact lens with an embedded stimulator chip.
Treatment Methods
The methods described here may comprise methods for treating dry eye and increasing tear production in a subject. The methods for increasing tear production may be used to treat a number of eye conditions and can provide immediate relief from discomfort and pain, as well as long-term improvements to overall ocular health. The treatment methods may involve one or more treatment regimens, such as providing stimulation to the cornea, conjunctiva, and/or subconjunctiva on an as-needed basis and/or according to a pre-determined regimen.
The method may be used to treat various forms of dry eye, including (but not limited to), chronic dry eye, episodic dry eye, seasonal dry eye, aqueous deficient dry eye, or evaporative dry eye. In some variations, the methods for increasing tear production may be used for treating DED caused by clinical factors, such as dysfunction of the lacrimal and/or meibomian glands. The treatment may also be for dry eye caused by external factors, such as medications, dehydration, and environmental pollutants. In some instances, the method may be used as a prophylactic measure to treat users who may be at an increased risk of developing dry eye, such as subjects who will undergo or who have undergone ocular surgery such as refractive vision correction and/or cataract surgery. In other instances, the method may be used to treat ocular allergies. For example, an increase in tear production may flush out allergens and other inflammatory mediators from the eyes.
In some variations, the methods for increasing tear production may be for increasing comfort for contact lens wearers. The system may be used in response to discomfort in order to decrease the discomfort associated with contact lens use. The system may also be used in response to discomfort to extend the time period for which an individual can comfortably wear contact lenses. Dryness and other conditions resulting from prolonged use of contact lenses may shorten the lifetime of contact lens use, which is often not past the age of forty. In some variations, the methods for increasing tear production may be for extending the number of years a contact lens user can wear contacts.
In some variations, the methods for increasing tear production may be for reducing the symptoms of tired eye in patients not diagnosed as having DED. Increased tear production may lead to more frequent blinking, which may in turn keep the eyes lubricated and reduce feelings of heaviness and strain.
Generally, the methods may comprise placing a device with a stimulator chip on the cornea or in the subconjunctiva of the eye of a subject. Because the nerves innervating the superior, inferior, and lateral portions of the conjunctiva (the supraorbital nerve, supratrochlear nerve, infratrochlear nerve, infraorbital nerve, and lacrimal nerve) go to the brain stem, stimulation of these nerves in only one eye may result in a bilateral tearing response. Accordingly, the step of placing a device on the cornea or in the subconjunctiva may involve placing the device in only one eye. For example, a subject may use a stimulating contact lens in one eye, and either no contact lens or a non-stimulating corrective contact lens in the other eye. In some variations, placement of the stimulating contact may be alternated between the eyes. In other variations, a subject may wear stimulating contact lenses in both eyes. Similarly, a stimulator chip may be implanted in only one eye to achieve a bilateral effect.
When the device comprises an implant configured to be implanted in the subconjunctival space, it may be implanted behind the lower eyelid, as described in more detail herein, where it can easily be periodically replaced (e.g., every six months) without any visible scarring. In some variations, an implantable device can be replaced by removing the old device and placing a new device in a position next to the previous position on the orbit (e.g., at the 5 o'clock position instead of the 6 o'clock position). This allows the former incision site to heal and recover. The next replacement of the implant may be put in yet another position near the old insertion site but still hidden behind the lower eyelid to avoid cosmetic impact. In some variations, the implantable device can be replaced by removing the old device and placing the new device in the opposite eye. This may reduce accommodation and/or minimize scarring.
In some instances, the eye may be imaged using high-resolution ultrasound, optical coherence tomography (OCT), or other imaging technique prior to implantation. The images may be used, for example, to assist in implanting the device (e.g., how deep to insert the implant based on the thickness of the conjunctiva or to verify that a patient is suitable for the procedure by possessing a conjunctiva that is thick enough to hold such an implanted device with a significant enough safety margin), selecting an appropriately sized/shaped implant for the patient's eye anatomy, and/or determining the source power needed to activate the stimulating chip.
After one or more contacts or implants is located on or in the eye, the methods may further comprise activating the stimulator chip using an external power source, and stimulating the cornea and/or conjunctiva to activate the reflex pathway and increase lacrimation and/or tear quality by increasing meibomian secretion or accessory gland secretion. In variations where the external power source is handheld, the handheld power source may be moved toward the eye, to a distance at which the external power source can deliver the intensity to generate the desired electrical stimulus. The distance can range from approximately 1 cm to approximately 1 m. Power sources at greater distances from the eye may require greater total power to activate the stimulator, due to light spread. In order to limit the total power output, and thus the potential for harming the iris, it may be desirable to have the distance be approximately 5-10 cm. In variations where the external power source is a mountable, the power source may have been mounted to a location adjacent to where the subject may look for extended periods of time, and the eye may be moved toward the external power source. When the external power source comprises an on/off switch, the power source may be turned on. If the stimulator chip is covered by an eyelid when the subject is looking forward, the eyeball (or, additionally or alternatively, the eyelid) may be moved to expose the stimulator chip to the power source.
Activation of the stimulator chip to generate a stimulus, which may in turn cause tearing or other effects, may be performed throughout the day on an as-needed basis and/or according to a pre-determined regimen. In some instances, a user may use one of the devices described herein to provide a round of stimulation when the user experiences symptoms of dry eye. A round of stimulation may have any suitable duration (e.g., between 1 second and 10 minutes). In other instances, the devices may be used to provide stimulation on a scheduled basis. For example, in some variations the devices described here may be used to provide a round of stimulation at least once daily, at least once weekly, or the like. In some variations, the devices may be used to deliver multiple rounds of stimulation each day (e.g., at least two treatments daily, at least four treatments daily, at least six times daily, between four and eight times daily, etc.) In some variations, the stimulation may be delivered at certain times of day. In other variations, the stimulation may be delivered at any time during the day as desired or determined by the user. When the device is used to provide stimulation on a scheduled basis, in some variations each round of stimulation may be the same length (e.g., about 30 seconds, about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes). In other variations, some rounds of stimulation may have different predetermined lengths. In yet other variations, the user may choose the length of the round of stimulation.
Methods of Manufacturing
In some variations, the methods described here comprise methods of manufacturing a contact lens that is configured to increase tear production by stimulating the cornea and/or conjunctiva. The manufacturing method is designed to reproducibly form a lens body with an embedded stimulator chip, where the stimulator chip is in a specific orientation and position within the lens body. Close proximity of the stimulator chip to the eye surface allows for effective stimulation of the cornea, conjunctiva, and/or subconjunctiva, while exposure of the stimulator chip to the eye may result in a foreign body sensation and irritation. Accordingly, in some variations, the stimulator chip may be within 5 microns, within 10 microns, or within 10-20 microns of the posterior surface of the lens.
Lathe Cutting
The methods of manufacturing a contact lens as described herein may comprise the step of embedding a stimulator chip in a lens body by sheet casting or rod casting. The method may further comprise the step of lathe cutting the casting to a desired shape.
When manufacturing the contact lens described here uses sheet casting, as shown in
When manufacturing a contact lens described here uses rod casting, as shown in
Once the buttons are formed using sheet casting or rod casting methods, the biomaterial with embedded stimulator chips may be lathe cut to a meniscus shape. The anterior and posterior lathe cuts may be achieved by blocking the button on a chuck using vacuum or wax. The radius may be cut to various shapes and dimensions including aspheric surfaces, toric surfaces, multifocal, diffractive, and the like. Typical shapes for contact lenses are meniscus lenses.
Control over spacing of the stimulator chip and the posterior surface of the lens may be achieved by appropriately locating the stimulator chip on the button surface during casting stages. Thickness may be controlled using a combination of casting and lathing processes to ensure that the stimulator chip is close to the posterior surface of the contact lens without being exposed, as described in more detail herein.
Cast Molding
In some variations, the methods of manufacturing a contact lens may comprise embedding a stimulator chip in a lens body and shaping the lens body by direct cast molding. Disposable or metal molds that follow the contour/shape of the lens shown in
To coat the second surface after cast molding, spray coating or thin-film coating may be employed. In some variations, as shown in
The final steps of processing may include hydration, cleaning, packaging, and sterilization or aseptic processing. An additional step of polishing, by tumble or pad for example, may be performed to achieve the surface quality desired.
This application is a divisional of U.S. patent application Ser. No. 14/920,847, filed Oct. 22, 2015, and titled “CONTACT LENS FOR INCREASING TEAR PRODUCTION,” which claims priority to U.S. Provisional Patent Application Ser. No. 62/067,395, filed on Oct. 22, 2014, and titled “CONTACT LENS FOR INCREASING TEAR PRODUCTION,” each of which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2512882 | Truesdale | Jun 1950 | A |
2525381 | Tower | Oct 1950 | A |
3620219 | Barker | Nov 1971 | A |
3709228 | Barker | Jan 1973 | A |
3885550 | MacLeod | May 1975 | A |
D257495 | Bros et al. | Nov 1980 | S |
4495676 | Hartmetz | Jan 1985 | A |
4520825 | Thompson et al. | Jun 1985 | A |
4539988 | Shirley et al. | Sep 1985 | A |
4590942 | Brenman et al. | May 1986 | A |
4628933 | Michelson | Dec 1986 | A |
4681121 | Kobal | Jul 1987 | A |
4684362 | Holt | Aug 1987 | A |
4706680 | Keusch et al. | Nov 1987 | A |
4735207 | Nambu et al. | Apr 1988 | A |
4777954 | Keusch et al. | Oct 1988 | A |
4780932 | Bowman et al. | Nov 1988 | A |
4868154 | Gilbard et al. | Sep 1989 | A |
4926880 | Claude et al. | May 1990 | A |
4957480 | Morenings | Sep 1990 | A |
4988358 | Eppley et al. | Jan 1991 | A |
5025807 | Zabara | Jun 1991 | A |
5072724 | Marcus | Dec 1991 | A |
5078733 | Eveleigh et al. | Jan 1992 | A |
5090422 | Dahl et al. | Feb 1992 | A |
5099829 | Wu | Mar 1992 | A |
5147284 | Fedorov et al. | Sep 1992 | A |
5324316 | Schulman et al. | Jun 1994 | A |
5342410 | Braverman | Aug 1994 | A |
5345948 | O'Donnell, Jr. | Sep 1994 | A |
5352445 | Lavaux | Oct 1994 | A |
5360438 | Fisher | Nov 1994 | A |
5498681 | Askari et al. | Mar 1996 | A |
5514131 | Edwards et al. | May 1996 | A |
5533470 | Rose | Jul 1996 | A |
5545617 | Dartt et al. | Aug 1996 | A |
5571101 | Ellman et al. | Nov 1996 | A |
5607461 | Lathrop | Mar 1997 | A |
5611970 | Apollonio et al. | Mar 1997 | A |
5640978 | Wong | Jun 1997 | A |
5683436 | Mendes et al. | Nov 1997 | A |
5697957 | Noren et al. | Dec 1997 | A |
5707400 | Terry et al. | Jan 1998 | A |
5713833 | Milligan | Feb 1998 | A |
5720773 | Lopez-Claros | Feb 1998 | A |
5733282 | Ellman et al. | Mar 1998 | A |
5735817 | Shantha | Apr 1998 | A |
5792100 | Shantha | Aug 1998 | A |
5794614 | Gruenke et al. | Aug 1998 | A |
5800685 | Perrault | Sep 1998 | A |
5843140 | Strojnik | Dec 1998 | A |
5900407 | Yerxa et al. | May 1999 | A |
5904658 | Niederauer et al. | May 1999 | A |
5935155 | Humayun et al. | Aug 1999 | A |
5948006 | Mann | Sep 1999 | A |
6001088 | Roberts et al. | Dec 1999 | A |
6020445 | Vanderlaan et al. | Feb 2000 | A |
6035236 | Jarding et al. | Mar 2000 | A |
6050999 | Paraschac et al. | Apr 2000 | A |
6051017 | Loeb et al. | Apr 2000 | A |
6083251 | Shindo | Jul 2000 | A |
6102847 | Stielau | Aug 2000 | A |
6152916 | Bige | Nov 2000 | A |
6200626 | Grobe, III et al. | Mar 2001 | B1 |
6205359 | Boveja | Mar 2001 | B1 |
6208902 | Boveja | Mar 2001 | B1 |
6240316 | Richmond et al. | May 2001 | B1 |
6246911 | Seligman | Jun 2001 | B1 |
6270796 | Weinstein | Aug 2001 | B1 |
6272382 | Faltys et al. | Aug 2001 | B1 |
6275737 | Mann | Aug 2001 | B1 |
6277855 | Yerxa | Aug 2001 | B1 |
6284765 | Caffrey | Sep 2001 | B1 |
6324429 | Shire et al. | Nov 2001 | B1 |
6327504 | Dolgin et al. | Dec 2001 | B1 |
6366814 | Boveja et al. | Apr 2002 | B1 |
6405079 | Ansarinia | Jun 2002 | B1 |
6438398 | Pflugfelder et al. | Aug 2002 | B1 |
6458157 | Suaning | Oct 2002 | B1 |
6505077 | Kast et al. | Jan 2003 | B1 |
6526318 | Ansarinia | Feb 2003 | B1 |
6535766 | Thompson et al. | Mar 2003 | B1 |
6537265 | Thanavala et al. | Mar 2003 | B2 |
6539253 | Thompson et al. | Mar 2003 | B2 |
6562036 | Ellman et al. | May 2003 | B1 |
6564102 | Boveja | May 2003 | B1 |
6578579 | Burnside et al. | Jun 2003 | B2 |
6604528 | Duncan | Aug 2003 | B1 |
6641799 | Goldberg | Nov 2003 | B2 |
6658301 | Loeb et al. | Dec 2003 | B2 |
6662052 | Sarwal et al. | Dec 2003 | B1 |
6684879 | Coffee et al. | Feb 2004 | B1 |
6701189 | Fang et al. | Mar 2004 | B2 |
6748951 | Schmidt | Jun 2004 | B1 |
6792314 | Byers et al. | Sep 2004 | B2 |
6829508 | Schulman et al. | Dec 2004 | B2 |
6853858 | Shalev | Feb 2005 | B2 |
6871099 | Whitehurst et al. | Mar 2005 | B1 |
6879859 | Boveja | Apr 2005 | B1 |
6885888 | Rezai | Apr 2005 | B2 |
6895279 | Loeb et al. | May 2005 | B2 |
7024241 | Bornzin et al. | Apr 2006 | B1 |
7054692 | Whitehurst et al. | May 2006 | B1 |
7067307 | Hochleitner et al. | Jun 2006 | B2 |
7069084 | Yee | Jun 2006 | B2 |
7117033 | Shalev et al. | Oct 2006 | B2 |
7142909 | Greenberg et al. | Nov 2006 | B2 |
7146209 | Gross et al. | Dec 2006 | B2 |
7169163 | Becker | Jan 2007 | B2 |
7190998 | Shalev et al. | Mar 2007 | B2 |
7225032 | Schmeling et al. | May 2007 | B2 |
7228184 | Heath | Jun 2007 | B2 |
7247692 | Laredo | Jul 2007 | B2 |
7317947 | Wahlstrand et al. | Jan 2008 | B2 |
7330762 | Boveja et al. | Feb 2008 | B2 |
7346389 | Newsome | Mar 2008 | B1 |
7346398 | Gross et al. | Mar 2008 | B2 |
7369897 | Boveja et al. | May 2008 | B2 |
7442191 | Hovda et al. | Oct 2008 | B2 |
7460911 | Cosendai et al. | Dec 2008 | B2 |
7477947 | Pines et al. | Jan 2009 | B2 |
7502652 | Gaunt et al. | Mar 2009 | B2 |
7547447 | Yiu et al. | Jun 2009 | B2 |
7565204 | Matei et al. | Jul 2009 | B2 |
7599737 | Yomtov et al. | Oct 2009 | B2 |
7636597 | Gross et al. | Dec 2009 | B2 |
7650186 | Hastings et al. | Jan 2010 | B2 |
D613408 | Gausmann et al. | Apr 2010 | S |
D614303 | Gausmann et al. | Apr 2010 | S |
D614774 | Gausmann et al. | Apr 2010 | S |
7725176 | Schuler et al. | May 2010 | B2 |
7725195 | Lima et al. | May 2010 | B2 |
D617443 | Grenon et al. | Jun 2010 | S |
7758190 | Korb et al. | Jul 2010 | B2 |
7778703 | Gross et al. | Aug 2010 | B2 |
7778711 | Ben-David et al. | Aug 2010 | B2 |
7792591 | Rooney et al. | Sep 2010 | B2 |
7805200 | Kast et al. | Sep 2010 | B2 |
7805202 | Kuzma et al. | Sep 2010 | B2 |
7805203 | Ben-David et al. | Sep 2010 | B2 |
7809442 | Bolea et al. | Oct 2010 | B2 |
7835794 | Greenberg et al. | Nov 2010 | B2 |
7846124 | Becker | Dec 2010 | B2 |
7860570 | Whitehurst et al. | Dec 2010 | B2 |
7873421 | Karell | Jan 2011 | B2 |
7879079 | Tu et al. | Feb 2011 | B2 |
D638128 | Prokop et al. | May 2011 | S |
7981095 | Grenon et al. | Jul 2011 | B2 |
7993381 | Mac et al. | Aug 2011 | B2 |
7998202 | Lesh | Aug 2011 | B2 |
8002783 | Vercellotti et al. | Aug 2011 | B2 |
8019419 | Panescu et al. | Sep 2011 | B1 |
8019441 | Wallace et al. | Sep 2011 | B2 |
8080047 | Yu | Dec 2011 | B2 |
8083787 | Korb et al. | Dec 2011 | B2 |
8145322 | Yao et al. | Mar 2012 | B1 |
8155746 | Maltan et al. | Apr 2012 | B2 |
8165680 | Greenberg et al. | Apr 2012 | B2 |
8204591 | Ben-David et al. | Jun 2012 | B2 |
8231218 | Hong et al. | Jul 2012 | B2 |
8251983 | Larson et al. | Aug 2012 | B2 |
8295529 | Petersen et al. | Oct 2012 | B2 |
8318070 | Shiah et al. | Nov 2012 | B2 |
D681839 | Nathanson | May 2013 | S |
8489189 | Tronnes | Jul 2013 | B2 |
8494641 | Boling et al. | Jul 2013 | B2 |
8521292 | Wei et al. | Aug 2013 | B2 |
8626298 | Simon | Jan 2014 | B2 |
8676324 | Simon et al. | Mar 2014 | B2 |
8728136 | Feldman | May 2014 | B2 |
8918181 | Ackermann et al. | Dec 2014 | B2 |
8936594 | Wolf et al. | Jan 2015 | B2 |
8986301 | Wolf et al. | Mar 2015 | B2 |
8996137 | Ackermann et al. | Mar 2015 | B2 |
9079042 | Tiedtke et al. | Jul 2015 | B2 |
9095723 | Ackermann et al. | Aug 2015 | B2 |
9265956 | Ackermann et al. | Feb 2016 | B2 |
9440065 | Ackermann et al. | Sep 2016 | B2 |
9687652 | Franke et al. | Jun 2017 | B2 |
9717627 | Kuzma et al. | Aug 2017 | B2 |
9737702 | Ackermann et al. | Aug 2017 | B2 |
9737712 | Franke et al. | Aug 2017 | B2 |
9764150 | Loudin et al. | Sep 2017 | B2 |
9770583 | Gupta et al. | Sep 2017 | B2 |
9821159 | Ackermann et al. | Nov 2017 | B2 |
9956397 | Loudin et al. | May 2018 | B2 |
D826420 | Ackermann et al. | Aug 2018 | S |
10143846 | Ackermann et al. | Dec 2018 | B2 |
D837396 | Ackermann et al. | Jan 2019 | S |
10207108 | Franke et al. | Feb 2019 | B2 |
20010018918 | Burnside et al. | Sep 2001 | A1 |
20010020177 | Gruzdowich et al. | Sep 2001 | A1 |
20020013594 | Dinger et al. | Jan 2002 | A1 |
20020035358 | Wang | Mar 2002 | A1 |
20020049290 | Vanderbilt | Apr 2002 | A1 |
20020188331 | Fang et al. | Dec 2002 | A1 |
20030014089 | Chow | Jan 2003 | A1 |
20030045909 | Gross et al. | Mar 2003 | A1 |
20030045911 | Bruchmann et al. | Mar 2003 | A1 |
20030114899 | Woods et al. | Jun 2003 | A1 |
20030120323 | Meadows et al. | Jun 2003 | A1 |
20030130809 | Cohen et al. | Jul 2003 | A1 |
20030139784 | Morimoto et al. | Jul 2003 | A1 |
20030176898 | Gross et al. | Sep 2003 | A1 |
20030192784 | Zhou | Oct 2003 | A1 |
20030229381 | Hochmair et al. | Dec 2003 | A1 |
20030233134 | Greenberg et al. | Dec 2003 | A1 |
20030233135 | Yee | Dec 2003 | A1 |
20040050392 | Tu et al. | Mar 2004 | A1 |
20040059466 | Block et al. | Mar 2004 | A1 |
20040098036 | Bergersen | May 2004 | A1 |
20040098067 | Ohta et al. | May 2004 | A1 |
20040127942 | Yomtov et al. | Jul 2004 | A1 |
20040138646 | Walla | Jul 2004 | A1 |
20040147973 | Hauser et al. | Jul 2004 | A1 |
20040151930 | Rouns et al. | Aug 2004 | A1 |
20040220644 | Shalev et al. | Nov 2004 | A1 |
20050004621 | Boveja et al. | Jan 2005 | A1 |
20050004625 | Chow | Jan 2005 | A1 |
20050010250 | Schuler et al. | Jan 2005 | A1 |
20050010266 | Bogdanowicz | Jan 2005 | A1 |
20050101967 | Weber | May 2005 | A1 |
20050101994 | Yamazaki et al. | May 2005 | A1 |
20050105046 | Tung | May 2005 | A1 |
20050137276 | Yahiaoui et al. | Jun 2005 | A1 |
20050159790 | Shalev | Jul 2005 | A1 |
20050197675 | David et al. | Sep 2005 | A1 |
20050251061 | Schuler et al. | Nov 2005 | A1 |
20050256570 | Azar | Nov 2005 | A1 |
20050267542 | David et al. | Dec 2005 | A1 |
20050268472 | Bourilkov et al. | Dec 2005 | A1 |
20060004423 | Boveja et al. | Jan 2006 | A1 |
20060018872 | Tew et al. | Jan 2006 | A1 |
20060074450 | Boveja et al. | Apr 2006 | A1 |
20060089673 | Schultheiss et al. | Apr 2006 | A1 |
20060095077 | Tronnes et al. | May 2006 | A1 |
20060095108 | Chowdhury et al. | May 2006 | A1 |
20060100668 | Ben-David et al. | May 2006 | A1 |
20060107958 | Sleeper | May 2006 | A1 |
20060142822 | Tulgar | Jun 2006 | A1 |
20060161225 | Sormann et al. | Jul 2006 | A1 |
20060195169 | Gross et al. | Aug 2006 | A1 |
20060206155 | Ben-David et al. | Sep 2006 | A1 |
20060206162 | Wahlstrand et al. | Sep 2006 | A1 |
20060216317 | Reinhard et al. | Sep 2006 | A1 |
20060235430 | Le et al. | Oct 2006 | A1 |
20060239482 | Hatoum et al. | Oct 2006 | A1 |
20060259098 | Erickson | Nov 2006 | A1 |
20060271024 | Gertner et al. | Nov 2006 | A1 |
20060271108 | Libbus et al. | Nov 2006 | A1 |
20060276738 | Becker | Dec 2006 | A1 |
20070031341 | DiMauro et al. | Feb 2007 | A1 |
20070038250 | He et al. | Feb 2007 | A1 |
20070038267 | Shodo et al. | Feb 2007 | A1 |
20070060815 | Martin et al. | Mar 2007 | A1 |
20070060954 | Cameron et al. | Mar 2007 | A1 |
20070083245 | Lamensdorf et al. | Apr 2007 | A1 |
20070123938 | Haller et al. | May 2007 | A1 |
20070135868 | Shi et al. | Jun 2007 | A1 |
20070150034 | Rooney et al. | Jun 2007 | A1 |
20070219600 | Gertner et al. | Sep 2007 | A1 |
20070237797 | Peyman | Oct 2007 | A1 |
20070237825 | Levy et al. | Oct 2007 | A1 |
20070248930 | Brawn | Oct 2007 | A1 |
20070250119 | Tyler et al. | Oct 2007 | A1 |
20070250135 | Bartz-Schmidt et al. | Oct 2007 | A1 |
20070255333 | Giftakis et al. | Nov 2007 | A1 |
20070276314 | Becker | Nov 2007 | A1 |
20070276451 | Rigaux | Nov 2007 | A1 |
20070295327 | Bottomley | Dec 2007 | A1 |
20070299420 | Peyman | Dec 2007 | A1 |
20070299462 | Becker | Dec 2007 | A1 |
20080009897 | Duran Von Arx | Jan 2008 | A1 |
20080021515 | Horsager et al. | Jan 2008 | A1 |
20080082057 | Korb et al. | Apr 2008 | A1 |
20080082131 | Llanos | Apr 2008 | A1 |
20080109054 | Hastings et al. | May 2008 | A1 |
20080114424 | Grenon et al. | May 2008 | A1 |
20080132933 | Gerber | Jun 2008 | A1 |
20080140141 | Ben-David et al. | Jun 2008 | A1 |
20080183242 | Tano et al. | Jul 2008 | A1 |
20080183243 | Shodo et al. | Jul 2008 | A1 |
20080208287 | Palermo et al. | Aug 2008 | A1 |
20080208335 | Blum | Aug 2008 | A1 |
20080221642 | Humayun et al. | Sep 2008 | A1 |
20080269648 | Bock | Oct 2008 | A1 |
20080288036 | Greenberg et al. | Nov 2008 | A1 |
20080294066 | Hetling et al. | Nov 2008 | A1 |
20090005835 | Greenberg et al. | Jan 2009 | A1 |
20090012573 | Karell | Jan 2009 | A1 |
20090018582 | Ishikawa et al. | Jan 2009 | A1 |
20090024187 | Erickson et al. | Jan 2009 | A1 |
20090024189 | Lee et al. | Jan 2009 | A1 |
20090036945 | Chancellor et al. | Feb 2009 | A1 |
20090043185 | Mcadams et al. | Feb 2009 | A1 |
20090056709 | Worsoff | Mar 2009 | A1 |
20090099600 | Moore et al. | Apr 2009 | A1 |
20090099623 | Bentwich | Apr 2009 | A1 |
20090099626 | de Juan, Jr. et al. | Apr 2009 | A1 |
20090101139 | Karell | Apr 2009 | A1 |
20090124965 | Greenberg et al. | May 2009 | A1 |
20090138061 | Stephens et al. | May 2009 | A1 |
20090156581 | Dillon et al. | Jun 2009 | A1 |
20090157142 | Cauller et al. | Jun 2009 | A1 |
20090157145 | Cauller | Jun 2009 | A1 |
20090157147 | Cauller et al. | Jun 2009 | A1 |
20090192571 | Stett et al. | Jul 2009 | A1 |
20090192575 | Carbunaru et al. | Jul 2009 | A1 |
20090204142 | Becker | Aug 2009 | A1 |
20090239235 | Demaria et al. | Sep 2009 | A1 |
20090241840 | Mills | Oct 2009 | A1 |
20090264966 | Blum et al. | Oct 2009 | A1 |
20090281594 | King et al. | Nov 2009 | A1 |
20090281596 | King et al. | Nov 2009 | A1 |
20090299418 | Shalev et al. | Dec 2009 | A1 |
20090306738 | Weiss et al. | Dec 2009 | A1 |
20090312818 | Horsager et al. | Dec 2009 | A1 |
20100030150 | Paques et al. | Feb 2010 | A1 |
20100076423 | Muller | Mar 2010 | A1 |
20100087896 | McCreery | Apr 2010 | A1 |
20100094280 | Muller | Apr 2010 | A1 |
20100100165 | Swanson et al. | Apr 2010 | A1 |
20100139002 | Walker et al. | Jun 2010 | A1 |
20100152708 | Li et al. | Jun 2010 | A1 |
20100161004 | Najafi et al. | Jun 2010 | A1 |
20100168513 | Pless et al. | Jul 2010 | A1 |
20100179468 | Becker | Jul 2010 | A1 |
20100211132 | Nimmagadda et al. | Aug 2010 | A1 |
20100241195 | Meadows et al. | Sep 2010 | A1 |
20100274164 | Juto | Oct 2010 | A1 |
20100274224 | Jain et al. | Oct 2010 | A1 |
20100274313 | Boling et al. | Oct 2010 | A1 |
20100280509 | Muller et al. | Nov 2010 | A1 |
20100288275 | Djupesland et al. | Nov 2010 | A1 |
20100311688 | Chapin et al. | Dec 2010 | A1 |
20100318159 | Aghassian et al. | Dec 2010 | A1 |
20110021975 | Covello | Jan 2011 | A1 |
20110028807 | Abreu | Feb 2011 | A1 |
20110028883 | Juan, Jr. et al. | Feb 2011 | A1 |
20110076775 | Stewart et al. | Mar 2011 | A1 |
20110077551 | Videbaek | Mar 2011 | A1 |
20110077698 | Tsampazis et al. | Mar 2011 | A1 |
20110081333 | Shantha et al. | Apr 2011 | A1 |
20110082518 | Filippello | Apr 2011 | A1 |
20110093043 | Torgerson et al. | Apr 2011 | A1 |
20110151393 | Frey et al. | Jun 2011 | A1 |
20110152969 | Zehnder et al. | Jun 2011 | A1 |
20110184490 | Horsager et al. | Jul 2011 | A1 |
20110202121 | Wen | Aug 2011 | A1 |
20110218590 | Degiorgio et al. | Sep 2011 | A1 |
20110234971 | Yeh | Sep 2011 | A1 |
20110270067 | Faraji | Nov 2011 | A1 |
20110270348 | Goetz | Nov 2011 | A1 |
20110275734 | Scales et al. | Nov 2011 | A1 |
20110276107 | Simon et al. | Nov 2011 | A1 |
20110282251 | Baker et al. | Nov 2011 | A1 |
20110295336 | Sharma et al. | Dec 2011 | A1 |
20110313330 | Loushin et al. | Dec 2011 | A1 |
20110313480 | De Vos | Dec 2011 | A1 |
20110313481 | De Vos | Dec 2011 | A1 |
20110313488 | Hincapie Ordonez et al. | Dec 2011 | A1 |
20120053648 | Neher et al. | Mar 2012 | A1 |
20120112903 | Kaib et al. | May 2012 | A1 |
20120130398 | Ackermann et al. | May 2012 | A1 |
20120133887 | Huang | May 2012 | A1 |
20120197338 | Su et al. | Aug 2012 | A1 |
20120232615 | Barolat et al. | Sep 2012 | A1 |
20120232618 | Feldman | Sep 2012 | A1 |
20120234332 | Shantha | Sep 2012 | A1 |
20120253249 | Wilson et al. | Oct 2012 | A1 |
20120298105 | Osorio et al. | Nov 2012 | A1 |
20120315329 | Ahn et al. | Dec 2012 | A1 |
20120316557 | Sartor et al. | Dec 2012 | A1 |
20120323214 | Shantha | Dec 2012 | A1 |
20120323227 | Wolf et al. | Dec 2012 | A1 |
20120323232 | Wolf et al. | Dec 2012 | A1 |
20120330376 | Flynn et al. | Dec 2012 | A1 |
20130006095 | Jenkins et al. | Jan 2013 | A1 |
20130006326 | Ackermann | Jan 2013 | A1 |
20130053733 | Korb et al. | Feb 2013 | A1 |
20130053737 | Scerbo | Feb 2013 | A1 |
20130065765 | Selifonov et al. | Mar 2013 | A1 |
20130158451 | Juto et al. | Jun 2013 | A1 |
20130158626 | Degiorgio et al. | Jun 2013 | A1 |
20130172790 | Badawi | Jul 2013 | A1 |
20130178937 | Vassallo et al. | Jul 2013 | A1 |
20130253387 | Bonutti et al. | Sep 2013 | A1 |
20130261706 | Mirro et al. | Oct 2013 | A1 |
20130270491 | Park et al. | Oct 2013 | A1 |
20130274824 | Otto et al. | Oct 2013 | A1 |
20130274831 | Otto et al. | Oct 2013 | A1 |
20130304154 | Goodman et al. | Nov 2013 | A1 |
20130310887 | Curtis | Nov 2013 | A1 |
20130336557 | Cruzat et al. | Dec 2013 | A1 |
20140012182 | Shantha | Jan 2014 | A1 |
20140056815 | Peyman | Feb 2014 | A1 |
20140081353 | Cook et al. | Mar 2014 | A1 |
20140088463 | Wolf et al. | Mar 2014 | A1 |
20140156000 | Campin et al. | Jun 2014 | A1 |
20140163580 | Tischendorf et al. | Jun 2014 | A1 |
20140214115 | Greiner et al. | Jul 2014 | A1 |
20140214118 | Greiner et al. | Jul 2014 | A1 |
20140214120 | Simon et al. | Jul 2014 | A1 |
20140214124 | Greiner et al. | Jul 2014 | A1 |
20140214125 | Greiner et al. | Jul 2014 | A1 |
20140257205 | Schaller | Sep 2014 | A1 |
20140257433 | Ackermann et al. | Sep 2014 | A1 |
20140277429 | Kuzma | Sep 2014 | A1 |
20140316310 | Ackermann et al. | Oct 2014 | A1 |
20140316396 | Wolf et al. | Oct 2014 | A1 |
20140316485 | Ackermann et al. | Oct 2014 | A1 |
20140362339 | Imafuku | Dec 2014 | A1 |
20140371565 | Glasser | Dec 2014 | A1 |
20140371812 | Ackermann et al. | Dec 2014 | A1 |
20150088156 | Ackermann et al. | Mar 2015 | A1 |
20150238754 | Loudin et al. | Aug 2015 | A1 |
20150335900 | Ackermann et al. | Nov 2015 | A1 |
20150362755 | Lee et al. | Dec 2015 | A1 |
20160022992 | Franke et al. | Jan 2016 | A1 |
20160058615 | Camras | Mar 2016 | A1 |
20160080720 | Fullam | Mar 2016 | A1 |
20160114163 | Franke et al. | Apr 2016 | A1 |
20160114172 | Loudin et al. | Apr 2016 | A1 |
20160121118 | Franke et al. | May 2016 | A1 |
20160158548 | Ackermann et al. | Jun 2016 | A1 |
20160270656 | Samec et al. | Sep 2016 | A1 |
20160367795 | Ackermann et al. | Dec 2016 | A1 |
20160367806 | Kahook | Dec 2016 | A1 |
20170049619 | Kahook | Feb 2017 | A1 |
20170157401 | Loudin et al. | Jun 2017 | A1 |
20170188947 | Connor | Jul 2017 | A1 |
20170239459 | Loudin et al. | Aug 2017 | A1 |
20170252563 | Franke et al. | Sep 2017 | A1 |
20170312521 | Franke et al. | Nov 2017 | A1 |
20170340884 | Franke et al. | Nov 2017 | A1 |
20170354536 | Kuzma et al. | Dec 2017 | A1 |
20170368332 | Ackermann et al. | Dec 2017 | A1 |
20170368333 | Loudin et al. | Dec 2017 | A1 |
20180064940 | Ackermann et al. | Mar 2018 | A1 |
20180064941 | Ackermann et al. | Mar 2018 | A1 |
20180064942 | Franke et al. | Mar 2018 | A1 |
20180153394 | Franke et al. | Jun 2018 | A1 |
20180154137 | Ackermann et al. | Jun 2018 | A1 |
20180154161 | Ackermann et al. | Jun 2018 | A1 |
20180161579 | Franke et al. | Jun 2018 | A1 |
20180280688 | Loudin et al. | Oct 2018 | A1 |
20190022392 | Franke et al. | Jan 2019 | A1 |
20190167978 | Ackermann et al. | Jun 2019 | A1 |
20190217095 | Franke et al. | Jul 2019 | A1 |
Number | Date | Country |
---|---|---|
1488331 | Apr 2004 | CN |
101087822 | Dec 2007 | CN |
101503491 | Aug 2009 | CN |
101589085 | Nov 2009 | CN |
101939043 | Jan 2011 | CN |
102266592 | Dec 2011 | CN |
103467652 | Dec 2013 | CN |
102006048819 | Apr 2008 | DE |
0109935 | May 1984 | EP |
1 497 483 | Jan 2005 | EP |
1 651 307 | May 2006 | EP |
1 919 553 | May 2008 | EP |
1 958 661 | Aug 2008 | EP |
2 205 193 | Jul 2010 | EP |
2 205 314 | Jul 2010 | EP |
3263175 | Jan 2018 | EP |
2129690 | Mar 1987 | GB |
2456002 | Jul 2009 | GB |
2102681-0001 | Oct 2012 | HK |
2199000-0001 | Mar 2013 | HK |
S60-500241 | Feb 1985 | JP |
2002-519138 | Jul 2002 | JP |
2002-325851 | Nov 2002 | JP |
2002-539859 | Nov 2002 | JP |
2004-508847 | Mar 2004 | JP |
2004-526510 | Sep 2004 | JP |
2005-502409 | Jan 2005 | JP |
2005-052461 | Mar 2005 | JP |
2005-144178 | Jun 2005 | JP |
2005-521489 | Jul 2005 | JP |
2005-528169 | Sep 2005 | JP |
2006-515900 | Jun 2006 | JP |
2006-311917 | Nov 2006 | JP |
2007-044323 | Feb 2007 | JP |
2007-528751 | Oct 2007 | JP |
2008-55000 | Mar 2008 | JP |
2008-183248 | Aug 2008 | JP |
2008-541850 | Nov 2008 | JP |
2009-506836 | Feb 2009 | JP |
2009-523503 | Jun 2009 | JP |
2010-505563 | Feb 2010 | JP |
2010-051562 | Mar 2010 | JP |
2010-506654 | Mar 2010 | JP |
2010-537777 | Dec 2010 | JP |
2011-030734 | Feb 2011 | JP |
2011-524780 | Sep 2011 | JP |
2012-100708 | May 2012 | JP |
2012-115545 | Jun 2012 | JP |
2012-200558 | Oct 2012 | JP |
2013-528416 | Jul 2013 | JP |
2338492 | Nov 2008 | RU |
WO-0001320 | Jan 2000 | WO |
WO-0056393 | Sep 2000 | WO |
WO-0062672 | Oct 2000 | WO |
WO-0185094 | Nov 2001 | WO |
WO-02078592 | Oct 2002 | WO |
WO-03023907 | Mar 2003 | WO |
WO-03082080 | Oct 2003 | WO |
WO-2003087433 | Oct 2003 | WO |
WO-03101535 | Dec 2003 | WO |
WO-2004026106 | Apr 2004 | WO |
WO-2004026106 | Apr 2004 | WO |
WO-2004043217 | May 2004 | WO |
WO-2004043217 | May 2004 | WO |
WO-2004091453 | Oct 2004 | WO |
WO-2004112893 | Dec 2004 | WO |
WO-2004112893 | Dec 2004 | WO |
WO-2005007234 | Jan 2005 | WO |
WO-2005007234 | Jan 2005 | WO |
WO-2005030025 | Apr 2005 | WO |
WO-2005030025 | Apr 2005 | WO |
WO-2005060984 | Jul 2005 | WO |
WO-2006127366 | Nov 2006 | WO |
WO-2007028003 | Mar 2007 | WO |
WO-2007079543 | Jul 2007 | WO |
WO-2008048321 | Apr 2008 | WO |
WO-2008156501 | Dec 2008 | WO |
WO-2008156501 | Dec 2008 | WO |
WO-2009035571 | Mar 2009 | WO |
WO-2009035571 | Mar 2009 | WO |
WO-2009048580 | Apr 2009 | WO |
WO-2009070709 | Jun 2009 | WO |
WO-2009154457 | Dec 2009 | WO |
WO-2010003011 | Jan 2010 | WO |
WO-2010027743 | Mar 2010 | WO |
WO-2010069317 | Jun 2010 | WO |
WO-2010099818 | Sep 2010 | WO |
WO-2010123704 | Oct 2010 | WO |
WO-2011011373 | Jan 2011 | WO |
WO-2012068247 | May 2012 | WO |
WO-2012139063 | Oct 2012 | WO |
WO-2012139063 | Oct 2012 | WO |
WO-2012155188 | Nov 2012 | WO |
WO-2013055940 | Apr 2013 | WO |
WO-2013055940 | Apr 2013 | WO |
WO-2013157320 | Oct 2013 | WO |
WO-2013162793 | Oct 2013 | WO |
WO-2013165697 | Nov 2013 | WO |
WO-2013166353 | Nov 2013 | WO |
WO-2014138709 | Sep 2014 | WO |
WO-2014165124 | Oct 2014 | WO |
WO-2014172693 | Oct 2014 | WO |
WO-2014172693 | Oct 2014 | WO |
WO-2015130707 | Sep 2015 | WO |
WO-2015130707 | Sep 2015 | WO |
WO-2016015025 | Jan 2016 | WO |
WO-2016025323 | Feb 2016 | WO |
WO-2016065211 | Apr 2016 | WO |
WO-2016065213 | Apr 2016 | WO |
WO-2016065215 | Apr 2016 | WO |
WO-2017192572 | Nov 2017 | WO |
WO-2014153218 | Sep 2019 | WO |
Entry |
---|
Olsen et al. “Human sclera: Thickness and surface area”. American Journal of Ophthalmology. Feb. 1998, vol. 125, Issue 2, pp. 237-241. |
Boberg-Ans J. (1955). “Experience in clinical examination of corneal sensitivity: corneal sensitivity and the naso-lacrimal reflex after retrobulbar anaesthesia,” Br. J. Ophthalmol. 39(12):705-726. |
Calonge (2001). “The Treatment of Dry Eye,” Survey Ophth. 45(2):S227-S239. |
Corrected Notice of Allowance dated Jun. 9, 2017, for U.S. Appl. No. 14/920,860, filed Oct. 22, 2015, 2 pages. |
Elsby et al. (1967). “Lacrimal Secretion in the Cat,” Br. J. Pharm. Chemother. 29(1):1-7. |
Extended European Search Report received for European Patent Application No. 11842076.9, dated Oct. 10, 2014, 5 pages. |
Extended European Search Report received for European Patent Application No. 12768458.7, dated Aug. 28, 2014, 7 pages. |
Extended European Search Report dated Oct. 21, 2016, for EP Application No. 14 778 719.6, filed on Mar. 12, 2014, 8 pages. |
Extended European Search Report dated Nov. 27, 2017, for EP Application No. 17 167 504.4, filed on Apr. 6, 2012, 9 pages. |
Final Office Action for U.S. Appl. No. 13/441,806, dated Mar. 12, 2015, 10 pages. |
Final Office Action for U.S. Appl. No. 13/441,806, dated May 20, 2016, 10 pages. |
Final Office Action for U.S. Appl. No. 14/816,846, dated May 11, 2016, 12 pages. |
Final Office Action received for U.S. Appl. No. 14/207,072, dated Jun. 22, 2016. |
Final Office Action dated Sep. 23, 2016, for U.S. Appl. No. 14/809,109, filed Jul. 24, 2015, 10 pages. |
Final Office Action dated Feb. 1, 2017, for U.S. Appl. No. 14/920,852, filed Oct. 22, 2015, 20 pages. |
Final Office Action dated Mar. 10, 2017, for U.S. Appl. No. 14/920,847, filed Oct. 22, 2015, 12 pages. |
Final Office Action dated May 17, 2017, for U.S. Appl. No. 13/441,806, filed Apr. 6, 2012, 5 pages. |
Final Office Action dated Sep. 1, 2017, for U.S. Appl. No. 14/816,846, filed Aug. 3, 2015, 12 pages. |
Final Office Action dated Dec. 20, 2017, for U.S. Appl. No. 14/920,852, filed Oct. 22, 2015, 18 pages. |
International Search Report & Written Opinion received for PCT Patent Application No. PCT/US2011/060989, dated Feb. 23, 2012, 16 pages. |
International Search Report & Written Opinion received for PCT Patent Application No. PCT/US2014/022158, dated Jul. 30, 2014, 8 pages. |
International Search Report and Written Opinion received for PCT Application No. PCT/US2015/042130, dated Oct. 28, 2015. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/057023, dated Mar. 4, 2016. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/024496, dated Aug. 22, 2014, 11 pages. |
International Search Report received for PCT Patent Application No. PCT/US2012/32629, dated Oct. 26, 2012, 4 pages. |
International Search Report received for PCT Patent Application No. PCT/US2015/57021, dated Feb. 10, 2016, 4 pages. |
International Search Report received for PCT Patent Application No. PCT/US2015/57019, dated Feb. 11, 2016, 4 pages. |
Lora et al. (2009). “Lacrimal Nerve Stimulation by a Neurostimulator for Tear Production,” Invest. Ophth. Vis. Science 50(13):172. |
Meng, I.D. et al. (2013). “The role of corneal afferent neurons in regulating tears under normal and dry eye conditions.” Exp. Eye Res. 117:79-87. |
Non Final Office Action received for U.S. Appl. No. 13/441,806, dated Sep. 17, 2015, 11 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/298,042, dated Oct. 2, 2013, 10 pages. |
Non-Final Office Action received for U.S. Appl. No. 13/441,806, dated Dec. 18, 2013, 9 pages. |
Non-Final Office Action received for U.S. Appl. No. 14/201,753, dated Apr. 2, 2015, 6 pages. |
Non-Final Office Action received for U.S. Appl. No. 14/809,109, dated Apr. 8, 2016, 8 pages. |
Non-Final Office Action received for U.S. Appl. No. 14/816,846, dated Sep. 11, 2015, 5 pages. |
Non-Final Office Action Received for U.S. Appl. No. 14/920,860, dated Aug. 17, 2016. |
Non-Final Office Action Received for U.S. Appl. No. 14/920,852, dated Aug. 1, 2016. |
Non Final Office Action received for U.S. Appl. No. 14/207,072, dated Dec. 9, 2015. |
Non-Final Office Action dated Sep. 27, 2016, for U.S. Appl. No. 14/920,847, filed Oct. 22, 2015, 13 pages. |
Non-Final Office Action dated Nov. 2, 2016, for U.S. Appl. No. 13/441,806, filed Apr. 6, 2012, 10pages. |
Non-Final Office Action dated Dec. 6, 2016, for U.S. Appl. No. 14/816,846, filed Aug. 3, 2015, 13 pages. |
Non-Final Office Action dated Jul. 17, 2017, for U.S. Appl. No. 15/598,063, filed May 17, 2017, 9 pages. |
Non-Final Office Action dated Jul. 31, 2017, for U.S. Appl. No. 14/920,852, filed Oct. 22, 2015, 18 pages. |
Notice of Allowance received for U.S. Appl. No. 14/201,753, dated Dec. 15, 2015, 2 pages. |
Notice of Allowance received for U.S. Appl. No. 14/201,753, dated Oct. 15, 2015, 5 pages. |
Notice of Allowance received for U.S. Appl. No. 13/298,042, dated Apr. 29, 2014, 5 pages. |
Notice of Allowance received for U.S. Appl. No. 13/298,042, dated Aug. 11, 2014, 7 pages. |
Notice of Allowance received for U.S. Appl. No. 13/298,042, dated Nov. 13, 2014, 5 pages. |
Notice of Allowance received for U.S. Appl. No. 14/561,107, dated Mar. 31, 2015, 7 pages. |
Notice of Allowance dated Dec. 19, 2016, for U.S. Appl. No. 14/809,109, filed Jul. 24, 2015, 8 pages. |
Notice of Allowance dated Jan. 19, 2017, for U.S. Appl. No. 14/920,860, filed Oct. 22, 2015, 5 pages. |
Notice of Allowance dated Mar. 21, 2017, for U.S. Appl. No. 14/809,109, filed Jul. 24, 2015, 8 pages. |
Notice of Allowance dated Mar. 28, 2017, for U.S. Appl. No. 14/207,072, filed Mar. 12, 2014, 8 pages. |
Notice of Allowance dated Apr. 20, 2017, for U.S. Appl. No. 14/920,860, filed Oct. 22, 2015, 5 pages. |
Notice of Allowance dated May 30, 2017, for U.S. Appl. No. 14/920,847, filed Oct. 22, 2015, 5 pages. |
Notice of Allowance dated Aug. 2, 2017, for U.S. Appl. No. 13/441,806, filed Apr. 6, 2012, 5 pages. |
Roessler et al. (2009). “Implantation and Explantation of a Wireless Epiretinal Retina Implant Device: Observations During the EPIRET3 Prospective Clinical Trial,” Invest. Ophthal. Visual Science 50(6):3003-3008. |
Ruskell (2004). “Distribution of Pterygopalatine Ganglion Efferents to the Lacrimal Gland in Man,” Exp. Eye Res. 78(3):329-335. |
Velikay-Parel et al. (2011). “Perceptual Threshold and Neuronal Excitability as Long-Term Safety Evaluation in Retinal Implants,” Invest. Opht. Visual Science E-Abstract 2590, 2 pages. |
Written Opinion received for PCT Patent Application No. PCT/US2012/032629, dated Oct. 26, 2012, 8 pages. |
Written Opinion received for PCT Patent Application No. PCT/US2015/57021, dated Feb. 10, 2016. |
Written Opinion received for PCT Patent Application No. PCT/US2015/57019, dated Feb. 11, 2016, 6 pages. |
“Vapor Pressure Data for H2O” (2012) Handbook of Chemistry and Physics, 73rd edition, 1 page. |
Acar et al. (2013) “Ocular Surface Assessment in Patients with Obstructive Sleep Apnea—Hypopnea Syndrome”, Sleep Breath, 17(2):583-588. Published online: Jun. 5, 2012. |
Amparo et al. (Jun. 2013) “Topical Interleukin 1 Receptor Antagonist for Treatment of Dry Eye Disease”, JAMA Ophthalmology, 131(6):715-723. |
Anonymous (Apr. 2007) “The Epidemiology of Dry Eye Disease: Report of the Epidemiology Subcommittee of the International Dry Eye WorkShop”, The Ocular Surface, 5(2):93-107. |
Bajpai et al. (Oct. 2012) “Preparation, Characterization and Water Uptake Behavior of Polysaccharide Based Nanoparticles”, Progresses in Nanotechnology and Nanomaterials, 1(1):9-17. |
Baraniuk et al. (2007) “Nasonasal Reflexes, the Nasal Cycle, and Sneeze”, Current Allergy and Asthma Reports, 7:105-111. |
Baroody et al. (Jun. 2009) “Fluticasone Furoate Nasal Spray Reduces the Nasal-Ocular Reflex: a Mechanism for the Efficacy of Topical Steroids in Controlling Allergic Eye Symptoms”, Journal of Allergy and Clinical Immunology, 123:1342-1348. |
Baroody et al. (Mar. 2008) “Nasal Ocular Reflexes and Eye Symptoms in Patients with Allergic Rhinitis”, Annals of Allergy, Asthma & Immunology, 100:194-199. |
Cipriano et al. (2014) “Superabsorbent Hydrogels that are Robust and Highly Stretchable”, American Chemical Society, 47(13):4445-4452. |
Dart et al. (2002) “Effects of 25% Propylene Glycol Hydrogel (Solugel) on Second Intention Wound Healing in Horses”, Veterinary Surgery, 31(4):309-313. |
Drummond (1995) “Lacrimation and Cutaneous Vasodilatation in the Face Induced by Painful Stimulation of the Nasal Ala and Upper Lip”, Journal of the Autonomic Nervous System, 51:109-116. |
Eye Health (Feb. 10, 2014) “Watery Eyes in Cold Weather”, Oregon Eye Specialists, PC, located at http://www.oregoneyes.net/watery-eyes-in-cold-weather/, 3 pages. |
Friedman (2010) “Impact of Dry Eye Disease and Impact on Quality of Life”, Current Opinion in Ophthalmology, 21:310-316. |
Friedman et al. (2016) “A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease”, Clinical Ophthalmology, 10:795-804. |
Fujisawa et al. (2002) “The Effect of Nasal Mucosal Stimulation on Schirmer Tests in Sjogren's Syndrome and Dry Eye”, Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3, Advances in Experimental Medicine and Biology, 506:1221-1226. |
Galor et al. (Apr. 2014) “Environmental Factors Affect the Risk of Dry Eye Syndrome in a United States Veteran Population”, Ophthalmology, 121(4):972-973. |
Gupta et al. (1997) “Nasolacrimal Stimulation of Aqueous Tear Production”, Cornea, 16(6):645-648. |
Harvard Health Publishing (Nov. 2010) “Dry Eyes and What You Can Try”, Harvard Medical School, 2 pages. |
Heigle et al. (1996) “Aqueous Tear Production in Patients with Neurotrophic Keratitis”, Cornea, 15(2):135-138. |
Holzer (1991) “Capsaicin: Cellular Targets, Mechanisms of Action, and Selectivity for Thin Sensory Neurons”, Pharamalogical Reviews, 43(2):143-201. |
Ikemura et al. (2008) “UV-VIS Spectra and Photoinitiation Behaviors of Acylphosphine Oxide and Bisacylphosphine Oxide Derivatives in unfilled, Light-Cured Dental Resins”, Dental Materials Journal, 27(6):765-774. |
Krupin et al. (Jan. 1977) “Decreased Basal Tear Production Associated with General Anesthesia”, Archives of Ophthalmology, 95:107-108. |
Loth et al. (1994) “Effect of Nasal Anaesthesia on Lacrimal Function After Nasal Allergen Challenge”, Clinical & Experimental Allergy, 24:375-376. |
Mallepally et al. (2013) “Superabsorbent Alginate Aerogels”, The Journal of Supercritical Fluids, 79:1-5. |
McDonald et al. (2009) “Hydroxypropyl Cellulose Ophthalmic Inserts (Lacrisert) Reduce the Signs and Symptoms of Dry Eye Syndrome and Improve Patient Quality of Life”, Transactions of the American Ophthalmological Society, 107:214-222. |
Pasqui et al. (2012) “Polysaccharide-Based Hydrogels: The Key Role of Water in Affecting 98. Mechanical Properties”, Polymers, 4(3):1517-1534. |
Petrov et al. (Jan. 2016) “SkQ1 Ophthalmic Solution for Dry Eye Treatment Results of a Phase 2 Safety and Efficacy Clinical Study in the Environment and During Challenge in the Controlled Adverse Environment Model”, Advances in Therapy, 33(1):96-115. |
Philip et al. (Dec. 1994) “The Human Nasal Response to Capsaicin”, Journal of Allergy and Clinical Immunology, 94:1035-1045. |
Sall et al. (Apr. 2000) “Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease”, Ophthalmology, 107(4):631-639. |
Shaari et al. (Apr. 1995) “Rhinorrhea is Decreased in Dogs after Nasal Application of Botulinum Toxin”, Otolaryngology Head and Neck Surgery, 112(4):566-571. |
Stjernschantz et al. (1979) “Electrical Stimulation of the Fifth Cranial Nerve in Rabbits: Effects on Ocular Blood Flow, Extravascular Albumin Content and Intraocular Pressure”, Experimental Eye Research, 28:229-238. |
Stjernschantz et al. (1980) “Vasomotor Effects of Facial Nerve Stimulation: Noncholinergic Vasodilation in the Eye”, Acta Physiologica Scandinavica, 109:45-50. |
Tsubota (1991) “The Importance of the Schirmer Test with Nasal Stimulation”, American Journal of Ophthalmology, 111(1):106-108. |
Van Setten et al. (Aug. 2016) “Evidence of Seasonality and Effects of Psychrometry in Dry Eye Disease”, Acta Ophthalmologica, 94:499-506. |
Yu, et al. (Apr. 2011) “The Economic Burden of Dry Eye Disease in the United States: a Decision Tree Analysis”, Cornea, 30(4):379-387. |
Zilstorff-Pedersen (May 1965) “Quantitative Measurements of the Nasolacrimal Reflex”, Archives of Otolaryngology, 81:457-462. |
Ahmed, E. M. et al. (2013, e-published Jul. 18, 2013). “Hydrogel: Preparation, characterization, and applications: A review,” Cairo University, Journal of Advanced Research (2015) 6, 105-121. |
Number | Date | Country | |
---|---|---|---|
20170368359 A1 | Dec 2017 | US |
Number | Date | Country | |
---|---|---|---|
62067395 | Oct 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14920847 | Oct 2015 | US |
Child | 15699905 | US |